PORCILIS M HYO

Main information

  • Trade name:
  • PORCILIS M HYO
  • Pharmaceutical form:
  • Suspension for injection
  • Medicine domain:
  • Animals
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • PORCILIS M HYO
    Malta
  • Language:
  • English

Therapeutic information

  • Therapeutic group:
  • Mycoplasma vaccine
  • Therapeutic area:
  • Pigs Food

Other information

Status

  • Source:
  • HMA - Europe
  • Authorization number:
  • FR/V/0158/001
  • Authorization date:
  • 18-11-2010
  • EU code:
  • FR/V/0158/001
  • Last update:
  • 09-08-2016

Summary of Product characteristics: dosage,interactions,side effects

SUMMARYOFPRODUCTCHARACTERISTICS

1. NAMEOFTHEVETERINARYMEDICINALPRODUCT

PorcilisMHyo,suspensionforinjection;

IT:PorsilisMHyo

2. QUALITATIVEANDQUANTITATIVECOMPOSITION

perdoseof2ml

Activesubstance

InactivatedwholecellconcentrateofMycoplasmahyopneumoniaestrain11:

7.0log

Ab

titre*

Adjuvant:150mgdl- 

-tocopherylacetate

*Meanantibodytitre(Ab)obtainedafterinoculationofmicewitha1/20pigdose.

Forafulllistofexcipients,seesection6.1.

3. PHARMACEUTICALFORM

Suspensionforinjection;whiteornearlywhite

4. CLINICALPARTICULARS

4.1 Targetspecies

Pig(finishingpigs)

4.2 Indicationsforuse,specifyingthetargetspecies

Forfinishingpigs:

Fortheactiveimmunisationofpigstoreducepulmonarylesionsduetoinfectionby

Mycoplasmahyopneumoniae.

Onsetofimmunity:2weeksafterthesecondinjection

Durationofimmunity:atleast20weeksafterthesecondinjection.

4.3 Contraindications

None

4.4 Specialwarnings

None

4.5 Specialprecautionsforuse

Specialprecautionsforuseinanimals

Vaccinateonlyhealthyanimals.

Specialprecautionstobetakenbythepersonadministeringtheveterinarymedicinal

producttoanimals

Incaseofaccidentalself-injection,seekmedicaladviceimmediatelyandshowthepackage

leafletorthelabeltothephysician.

4.6 Adversereactions(frequencyandseriousness)

Ameantransienttemperatureincreaseinbodytemperatureofabout0.3

C,inindividual

pigsupto2.0

C,mayoccuronthefirst1to2daysaftervaccination.Theanimalsreturn

tonormalthenextday.Atransientswelling/redness(max.diameter5cm)mayoccurat

theinjectionsitediminishingoveraperiodofmaximally14days.

Inisolatedcaseshypersensitivityreactionsmayoccur.

4.7 Useduringpregnancy,lactationorlay

Notapplicable

4.8 Interactionwithothermedicinalproductsandotherformsofinteraction

Safetyandefficacydataareavailableinpigsfrom4weeksofageonwards,which

demonstratethatthisvaccinecanbemixedwithPorcilisPRRS.

TheproductliteratureofPorcilisPRRSshouldalsobeconsultedbeforeadministrationof

themixedproduct.

Noinformationisavailableonthesafetyandefficacyofthisvaccinewhenusedwithany

otherveterinarymedicinalproductexcepttheproductmentionedabove.Adecisiontouse

thisvaccinebeforeorafteranyotherveterinarymedicinalproductthereforeneedstobe

madeonacasebycasebasis.Noinformationisavailableonthesafetyandefficacyofthe

useofPorcilisMHyomixedwithPorcilisPRRSinbreedinganimalsorduringpregnancy.

4.9 Amountstobeadministeredandadministrationroute

Intramuscularinjectioninpigsof2mlperanimalintheneckintheareabehindtheear.

Vaccinationscheme:

Vaccinatepigstwicewithathreeweekinterval.Thefirstinjectioncanbegivenfroman

ageof1weekonwards.

ForsimultaneoususewithPorcilisPRRSinfinishingpigsfrom4weeksofage(3weeks

afterpriming)thevaccinemaybeusedforreconstitutionshortlybeforevaccination.

Therebythefollowinginstructionsshouldbeused:

PorcilisPRRS PorcilisMHyo

10doses + 20ml

25doses + 50ml

50doses + 100ml

100doses + 200ml

Asingledose(2ml)ofPorcilisMHyomixedwithPorcilisPRRSisgivenintramuscularly

intheneck.

Beforeusingthevaccineallowittoreachroomtemperature(15-25

C)andshakewell

beforeuse.

Usesterilesyringesandneedles.

Avoidintroductionofcontamination.

4.10Overdose(symptoms,emergencyprocedures,antidotes),ifnecessary

Noadversereactionsotherthanalreadymentionedundersection“Adversereactions”have

beenobservedafteradministrationofadoubledose.

4.11Withdrawalperiod(s)

Zerodays

5. IMMUNOLOGICALPROPERTIES

Pharmacotherapeuticgroup:Inactivatedbacterialvaccine

ATCvetcode:QI09AB13

PorcilisMHyoisaninactivatedbacterialvaccinecontainingwholecellconcentrateof

Mycoplasmahyopneumoniaestrain11.Thisantigenisincorporatedinanadjuvantbasedon

dl-α-tocopherylacetateinordertogiveaprolongedstimulationofimmunity.Theproduct

stimulatesthedevelopmentofactiveimmunityinpigsagainstMycoplasmahyopneumoniae.

6. PHARMACEUTICALPARTICULARS

6.1 Listofexcipients

dlα-tocopherylacetate

Polysorbate80

Simethicone

Sodiumchloride

Sodiumdihydrogenphosphate

Disodiumhydrogenphosphate

Waterforinjection

6.2 Incompatibilities

DonotmixwithanyotherveterinarymedicinalproductexceptwithPorcilisPRRS.

6.3 Shelflife

Shelf-lifeoftheveterinarymedicinalproductaspackagedforsale:3years

Shelf-lifeafterfirstopeningtheimmediatepackaging:3hours.

ShelflifeaftermixingwithPorcilisPRRS:1hour(atroomtemperature)

6.4 Specialprecautionsforstorage

Storeinarefrigerator(2

C–8

C).Donotfreeze.

6.5 Natureandcompositionofimmediatepackaging

Cardboardboxeswitheither1PETvialof20,50,100,200or250ml,5PETvialsof20,50,

100,200or250mlor10PETvialsof20,50,100,200or250ml.Vialsareclosedwitha

halogenobutylrubberstopperandacodedaluminiumcap.

Notallpacksizesmaybemarketed.

6.6 Specialprecautionsforthedisposalofunusedveterinarymedicinalproductorwaste

materialsderivedfromtheuseofsuchproducts

Anyunusedveterinarymedicinalproductorwastematerialsderivedfromsuchveterinary

medicinalproductshouldbedisposedofinaccordancewithlocalrequirements.

7. MARKETINGAUTHORISATIONHOLDER

IntervetInternationalB.V. Representedbythenationalcompanies

WimdeKörverstraat35 intheMemberStates

NL-5831ANBoxmeer

TheNetherlands

8. MARKETINGAUTHORISATIONNUMBER(S)

9. DATEOFFIRSTAUTHORISATION/RENEWALOFTHEAUTHORISATION

FR:28June2004

10. DATEOFREVISIONOFTHETEXT

November2010

PROHIBITIONOFSALE,SUPPLYAND/ORUSE

Notapplicable.

5-9-2018

Outcome of the pesticides peer review meeting on general recurring issues in mammalian toxicology

Outcome of the pesticides peer review meeting on general recurring issues in mammalian toxicology

Published on: Tue, 04 Sep 2018 00:00:00 +0200 This technical report reflects the outcome of the mammalian toxicology experts meeting on general recurring issues noted during the EFSA peer reviews of pesticide active substances under Regulation (EC) No 1107/2009. The main issues identified were related to genotoxicity of products and principles of (Q)SAR and read‐across. General presentations on the different EFSA guidance and EFSA developmental activities related to human health risk assessment of pesti...

Europe - EFSA - European Food Safety Authority Publications

1-10-2018

MS-H vaccine (Pharmsure Veterinary Products Europe Ltd)

MS-H vaccine (Pharmsure Veterinary Products Europe Ltd)

MS-H vaccine (Active substance: Mycoplasma synoviae Strain MS-H live attenuated thermosensitive) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)6404 of Mon, 01 Oct 2018 European Medicines Agency (EMA) procedure number: EMEA/V/C/161/T/11

Europe -DG Health and Food Safety

29-6-2018

Porcilis PCV M Hyo (Intervet International B.V.)

Porcilis PCV M Hyo (Intervet International B.V.)

Porcilis PCV M Hyo (Active substance: Porcine circovirus and Mycoplasma hyopneumoniae vaccine (inactivated)) - Centralised - 2-Monthly update - Commission Decision (2018)4166 of Fri, 29 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/V/C/3796/II/7

Europe -DG Health and Food Safety